Zimbabwe has turned down a significant American health deal valued at 367 million US dollars (£272m) spanning five years due to the United States' insistence on confidential biological samples.
This move became public following a internal memorandum dated December was disclosed, which showed Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government representative later stated that the United States was demanding access to health data for research and commercial gain but was unwilling to guarantee the benefits from any future treatments.
"We will now turn to the challenging and unfortunate process of scaling back our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had furnished over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for further talks to secure a deal acceptable to both sides so the country's critical HIV treatment initiative can be sustained.
Broader Implications
Zimbabwe's decision comes after a similar case in neighbouring Kenya, where a high court halted a similar deal with the US following legal challenges were raised about the safety of citizens' health data.
Since returning to the presidency recently, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
The agency had overseen aid for the US government, but Trump argued its expenditure was "inefficient" and his administration was seeking government-to-government deals to enhance transparency and accountability.
According to reports, Sixteen nations in Africa have so far agreed to similar agreements, constituting more than $18.3bn in new funding.
Details of the Declined Deal
This assistance for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership would have delivered extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million presently on HIV treatment through US-supported initiatives," Tremont commented.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to share its biological resources and data for a long time, with no corresponding assurance of access to any scientific breakthroughs – such as new medicines or tests – that could be developed from that provided information," he stated.
"Effectively, our country would supply the basic resources for scientific discovery with no certainty that the end products would be available to our people should a new disease outbreak emerge."
Sovereignty and International Frameworks
He also said that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were disrupting frameworks previously set up through the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing framework designed to deal with future pandemics.
"This framework is intended to guarantee that when a nation contributes its samples, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised solely by those with the funds to create them."
The government's concerns regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We are open to continued dialogue with our US partners on how subsequent collaboration might be arranged in a way that respects the independence and interests of both nations."
Health Experts Response
Medical experts expressed it recognised the government's concerns, but urged that negotiations must proceed given that much of the nation's HIV programmes relied on international support.
"If specific concerns arise, such as those involving information security or agreement terms, these can frequently be resolved through detailed discussion and mutually agreed protections," it said.
The halted deal highlights the continuing tensions between receiving vital foreign assistance and protecting national sovereignty in an increasingly interconnected world.